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light of the higher antibiotic-resistance reported in bioﬁlm-
growing bacteria, our ﬁndings on the role of anaerobes in
the occluding process should be considered in selecting and
dosing antibiotics for the prophylaxis of biliary stent block-
age.
doi:10.1016/j.ijid.2008.05.150
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The Public Health Perspective
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The introduction of antiretroviral therapy has changed the
course of HIV disease by improving survival rates. But ART
has equal potential for prevention, since it reduces the HIV
RNA level and the probability of HIV transmission from an
infected person to their sexual partners. Currently NIH is
undertaking a large randomized clinical trial (HPNT052) in
serodiscordant couples to study the effect of antiretrovi-
ral therapy in preventing HIV transmission to their partner.
Although there have been no randomized controlled clini-
cal trials on the subject, antiretroviral drugs are currently
used in clinical practice for post-exposure prophylaxis after
inadvertent occupational exposure or after sexual exposure
to the virus. The success story in using antiretrovirals for
HIV prevention has been shown from trials involving Mother
to child HIV transmission interventions. Hence Can Expanded
Treatment through the Public Health approach slow the AIDS
Epidemic?
doi:10.1016/j.ijid.2008.05.151
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This presentation explores existing and potential behav-
ioral and social science contributions to consideration of
the impacts of expanded antiretroviral (ARV) scale-up on
the global HIV epidemic. Behavioral science literature com-
monly evaluates sexual behavior (‘‘risk compensation’’) and
medication adherence. While such analyses are critical to
evaluation of overall impact and will be reviewed here,
the presenter seeks to highlight approaches and empirical
research that set (and sometimes problematize) such typi-
cally individually-based approaches in their social, cultural,
political, economic, and human-rights/ethical contexts. It,
furthermore, brings behavioral and social science contri-
butions to bear on the critical question of: ‘‘how do we
deﬁne and measure success?’’ The presentation addresses
the ways in which interdisciplinary behavioral and social
science work can illuminate key questions about feasibility
and sustainability as well as ‘‘unintended consequences’’ of
these biomedical interventions on non-biomedical HIV pre-
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ention interventions and social and health systems. From
practical standpoint, such analyses can 1) assist identi-
cation of appropriate methods and criteria to evaluate
mpacts; 2) assist targeting and revision of patient and com-
unity educational materials and involvement strategies;
nd 3) aid development of uptake, retention and medica-
ion and general program adherence schemes that more
xplicitly address economic, cultural, and social barriers.
systematic analysis of lay media (primarily print sources)
bout recent ARV scale-up will be used as a case study
o demonstrate how social/behavioral science perspectives
ay shed light on popular conceptions of such programs and
echnologies, how scientiﬁc information is interpreted by
edia and the general public, and how consequential mis-
onceptions may arise. In the overall presentation, special
mphasis is placed on examination of approaches and per-
pectives that are likely to inform questions and solutions
elevant to both ARV treatment and biomedical prevention
echnologies under testing, particularly implementation of
RV pre-exposure prophylaxis.
oi:10.1016/j.ijid.2008.05.152
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ackground: With the exception of male circumcision and
ome behavioural interventions, randomised controlled tri-
ls (RCTs) of HIV prevention interventions have reported
isappointing results. In this presentation, data on post-
xposure prophylaxis (PEP, the provision of anti-retrovirals
ARVs) after exposure to prevent HIV infection) and
re-exposure prophylaxis (Pre-EP, ARVs provided before
xposure to prevent infection) will be reviewed.
Methods: A guided literature review on the efﬁcacy,
ost-effectiveness, implementation policy and likely public
ealth impact of PEP and pre-EP was conducted.
Results: No RCTs examining the efﬁcacy of PEP were iden-
iﬁed. Nevertheless, a variety of animal and observational
vidence suggests that PEP prescribed within 72 hours of HIV
xposure is likely to substantially reduce the risk of HIV
ransmission. PEP use at the population level is generally
ot cost-effective, unless its use is highly targeted towards
he highest risk exposures. Despite these limitations, poli-
ies recommending PEP after sexual and other HIV exposures
xist in many settings. Although it is possible that post-
P may prevent cases of transmission, a substantial public
ealth impact on the HIV epidemic is unlikely. RCTs eval-
ating the efﬁcacy of Pre-EP are currently underway in a
umber of settings. Animal data strongly suggest that Pre-
P will need to consist of combinations of more than one
RV. The cost effectiveness of Pre-EP will depend strongly
n the risk setting. No locations were identiﬁed which cur-
ently recommend Pre-EP, and there has been little study of
he potential public health impact of this preventive inter-
ention.
Conclusion: PEP is being increasingly utilized as a form of
IV prevention, despite the lack of any efﬁcacy data from
